How should Novolog 70/30 (insulin lispro 70/30) be initiated, titrated, administered, monitored, and what safety considerations and second‑line options apply for an adult insulin‑naïve patient?

NovoLog 70/30 Management in Insulin-Naïve Adults

For insulin-naïve adults with type 2 diabetes requiring NovoLog 70/30, initiate at a total daily dose based on weight (0.2-0.4 units/kg/day), split into two doses given before breakfast (2/3 of total) and before dinner (1/3 of total), administered within 15 minutes before meals. 1

Initiation Strategy

Start NovoLog 70/30 twice daily when:

• A1C >10% (>86 mmol/mol) or blood glucose ≥300 mg/dL with symptoms of hyperglycemia 2
• Patient requires both basal and prandial coverage but cannot manage multiple daily injections
• Critical limitation: The fixed 70/30 ratio does not allow separate basal versus prandial adjustments 1

Dosing Algorithm

Initial dose calculation:

• Total daily dose: 0.2-0.4 units/kg/day (conservative start at 0.2 units/kg for most patients to minimize hypoglycemia risk)
• Morning dose (before breakfast): 2/3 of total daily dose
• Evening dose (before dinner): 1/3 of total daily dose 2

Example: For a 100 kg patient:

• Total daily dose: 20-40 units (start at 20 units)
• Morning: ~13 units
• Evening: ~7 units

Administration Technique

Critical preparation steps 1:

1. Always inspect visually - must appear uniformly white and cloudy (do not use if clear or contains particles)
2. Resuspension is mandatory before each injection:
   • Roll vial horizontally 10 times in hands
   • For FlexPen: roll horizontally 10 times, then invert 10 times until glass ball moves end-to-end
3. Inject subcutaneously in abdomen, buttocks, thigh, or upper arm
4. Timing: Within 15 minutes before meal initiation (may give immediately after meal in type 2 diabetes if needed)
5. Rotate injection sites within same region to prevent lipodystrophy and localized cutaneous amyloidosis

Absolute contraindications to administration 1:

• Never administer intravenously
• Never use in insulin pumps
• Never mix with other insulins

Titration Protocol

Titrate every 3 days based on self-monitored blood glucose 2:

• Target fasting plasma glucose: individualized (typically 80-130 mg/dL for most adults)
• Increase by 2 units per dose if above target without hypoglycemia
• For hypoglycemia: Determine cause; if no clear reason, decrease corresponding dose by 10-20% 2

Reassess every 3-6 months to avoid therapeutic inertia 2

Monitoring Requirements

Blood glucose monitoring:

• Minimum: Fasting and pre-dinner glucose daily during titration
• Increase frequency with:
  • Dose changes
  • Changes in physical activity or meal patterns
  • Acute illness
  • Renal or hepatic impairment 1

Watch for overbasalization signals 2:

• Elevated bedtime-to-morning glucose differential
• Elevated postprandial-to-preprandial differential
• Hypoglycemia (aware or unaware)
• High glucose variability

Safety Considerations

Hypoglycemia risk 1, 3:

• Prescribe glucagon for all patients on NovoLog 70/30
• Educate patient and family on recognition and treatment
• In patients >65 years: expect slightly higher major hypoglycemia rates (0.14 vs 0.05 episodes per patient-year) but still acceptable 3

Common pitfalls:

• Medication errors: Always verify insulin label before injection - accidental mix-ups between insulin products are common 1
• Never share FlexPens between patients even if needle changed (risk of bloodborne pathogen transmission) 1
• Lipodystrophy: Rotate sites consistently; do not inject into areas of lipodystrophy as this alters absorption 1

Dosage adjustments needed with 1:

• Changes in renal function (may need dose reduction)
• Changes in hepatic function (may need dose reduction)
• Concomitant medications (corticosteroids increase requirements; certain oral agents may increase hypoglycemia risk)

Second-Line Options

If A1C remains above goal on optimized NovoLog 70/30 2:

1. Add GLP-1 RA or dual GIP/GLP-1 RA if not already prescribed (consider fixed-ratio combination products like IDegLira or iGlarLixi if available)
2. Consider switching to basal-bolus regimen (separate basal and rapid-acting insulins) to allow independent basal versus prandial adjustments
3. Add SGLT2 inhibitor for cardiovascular/renal benefits if appropriate

The fixed 70/30 ratio is a significant limitation - if patient needs different basal versus prandial coverage ratios, transition to separate basal and prandial insulins 1.

Not recommended for 1:

• Diabetic ketoacidosis treatment
• Patients requiring flexible basal versus prandial dose adjustments
• Type 1 diabetes (insufficient evidence; basal-bolus preferred) 4